We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability. But there are ample reasons to avoid buying MRNA stock today.
Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population. Regulatory submissions for mRNA-1010 are in progress in the US, Europe, Canada, and Australia, with the US FDA reviewing the data and an approval decision expected later this year. Separately, Moderna advanced its mRNA-based hantavirus vaccine collaboration with Korea University's Vaccine Innovation...
Investing.com -- Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.
Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.